Clinical Trial Results:
A PHASE II, OPEN LABEL, RANDOMISED, SINGLE CENTRE STUDY TO EVALUATE THE SAFETY, REACTOGENICITY AND IMMUNOGENICITY OF THREE OR FOUR DOSES OF MENINGOCOCCAL SEROGROUP B OUTER MEMBRANE VESICLE (OMV) VACCINE MENZBTM WHEN ADMINISTERED TO HEALTHY ADULTS (UNIVERSITY STUDENTS)
Summary
|
|
EudraCT number |
2005-003570-22 |
Trial protocol |
GB |
Global completion date |
30 Mar 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 Jan 2019
|
First version publication date |
02 Jan 2019
|
Other versions |
|
Summary report(s) |
Immunogenicity of three (0,12 and 60 weeks) of four (0,6,12 and 60 weeks)doses of the meningococcal serogroup B outer membrane vesicle vaccine MeNZB when administered to healthy adults Immunogenicity of three (0,12 and 60 weeks) of four (0,6,12 and 60 weeks)doses of the meningococcal serogroup B outer membrane vesicle vaccine MeNZB when administered to healthy adults |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.